CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 2898-2903

  Van Rijnsoever, Marius ^a,b   Elsaleh, Hany ^c   Joseph, David ^b   McCaul, Kieran ^a   Iacopetta, Barry ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MOLECULAR MARKER; PROTEIN P53;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COHORT STUDIES; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA SEQUENCE, UNSTABLE; FEMALE; FLUOROURACIL; GENES, P53; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASMS; PHENOTYPE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0041524111     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jones, P. A., and Laird, P. W. Cancer epigenetics comes of age. Nat. Genet., 21: 163-167, 1999.
2. Toyota, M., Ahuja, N., Ohe-Toyota, M. Herman, J. G., Baylin, S. B., and Issa, J. P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA, 96: 8681-8686, 1999.
3. Toyota, M., Ohe-Toyota, M., Ahuja, N., and Issa, J. P. Distinct genetic profiles in colorectal tumors with of without the CpG island methylator phenotype. Proc. Natl. Acad. Sci. USA, 97: 710-715, 2000.
4. Van Rijnsoever, M., Grieu, F., Elsaleh, H., Joseph, D., and Iacopetta, B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut, 51: 797-802, 2002.
5. Hawkins, N., Norrie, M., Cheong, K., Mokany, E., Ku, S. L., Meagher, A., O'Connor, T., and Ward, R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology, 122: 1376-1387, 2002.
6. Kane, M. F., Loda, M., Gaida, G. M., Lipman, J., Mishra, R., Goldman, H., Jessup, J. M., and Kolodner, R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res., 57: 808-811, 1997.
7. Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J. P., Markowitz, S., Willson, J. K., Hamilton, S. R., Kinzler, K. W., Kane, M. F., Kolodner, R. D., Vogelstein, B., Kunkel, T. A., and Baylin, S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.
8. Ahuja, N., Mohan, A. L., Li, Q., Stolker, J. M., Herman, J. G., Hamilton, S. R., Baylin S. B., and Issa, J. P. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res., 57: 3370-3374, 1997.
9. Shannon, B. A., and Iacopetta, B. J. Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Lett., 167: 91-97, 2001.
10. INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol. Biomark. Prev., 8: 501-506, 1999.
11. Jass, J. R. Serrated route to colorectal cancer: back street or super highway? J. Pathol., 193: 283-285, 2001.
12. Hawkins, N., and Ward, R. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J. Natl. Cancer Inst. (Bethesda), 93: 1307-1313, 2001.
13. Elsaleh, H., Joseph, D., Grieu, F., Zeps, N., Spry, N., and Iacopetta, B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet, 355: 1745-1750, 2000.
14. Elsaleh, H., Powell, B., McCaul, K., Grieu, F., Grant, R., Joseph, D., and Iacopetta, B. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res., 7: 1343-1349, 2001.
15. Liang, J. T., Huang, K. C., Lai, H. S., Lee, P. H., Cheng, Y. M., Hsu, H. C., Cheng, A. L., Hsu, C. H., Yeh, K. H., Wang S. M., Tang, C., and Chang, K. J. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int. J. Cancer, 101: 519-525, 2002.
16. Taal, B. G., Van Tinteren, H., and Zoetmulder, F. A. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br. J. Cancer, 85: 1437-1443, 2001.
17. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
18. Iacopetta, B., and Grieu, F. Routine detection of the replication error phenotype in clinical tumor specimens using fluorescence-SSCP. Biotechniques, 28: 566-570, 2000.
19. Iacopetta, B., Elsaleh, H., Grieu, F., Joseph, D., Sterrett, G., and Robbins, P. Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism. Diagn. Mol. Pathol., 9: 20-25, 2000.
20. Lin, D. Y., Psaty, B. M., and Kronmal, R. A. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics, 54: 948-963, 1998.
21. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med., 122: 321-326, 1995.
22. 0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology (Basel), 57: 149-156, 1999.
23. INK4a methylation and p53 mutational status. Cancer Res., 60: 129-133, 2000.
24. Ahnen, D. J., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L. C., Bunn, P. A., Jr., Stemmerman, G., Wells, J. D., Macdonald, J. S., and Meyskens, F. L., Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res., 58: 1149-1158, 1998.
25. Sundararajan, V., Mitra, N., Jacobson, J. S., Grann, V. R., Heitjan, D. F., and Neugut, A. I. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann. Intern. Med., 136: 349-357, 2002.
26. Lenz, H. J., Hayashi, K., Salonga, D., Danenberg, K. D., Danenberg, P. V., Metzger, R., Banerjee, D., Bertino, J. R., Groshen, S., Leichman, L. P., and Leichman, C. G. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res., 4: 1243-1250, 1998.
27. Leichman, C. G., Lenz, H. J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., and Danenberg, P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol., 15: 3223-3229, 1997.
28. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., Lenz, H. J., Leichman, C. G., Leichman, L., Diasio, R. B., and Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res., 6: 1322-1327, 2000.
29. Choi, S. W., and Mason, J. B. Folate and carcinogenesis: an integrated scheme. J. Nutr., 130: 129-132, 2000.